[Osteoporosis and anti-androgenic therapy in case of prostate cancer].
Anti-androgenic therapy for prostate cancer is associated with an increased risk of osteoporosis and of fracture. A fracture occurence has negative influence on survival. An antiresorptive agent like zoledronate, prevents bone loss consecutive to anti-androgenic therapy.
Uebelhart
B
B
Service des maladies osseuses, Centre collaborateur de I'OMS pour la prevention de l'ostéoporose, Département de rehabilitation et gériatrie, Hôpitaux universitaires de Genève. brigitte.uebelhart@hcuge.ch
Rizzoli
R
R
D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use*; D001862:Bone Resorption / Q000139:chemically induced / Q000188:drug therapy; D004164:Diphosphonates / Q000627:therapeutic use; D050723:Fractures, Bone / Q000209:etiology; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000150:complications; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012307:Risk Factors; D013534:Survival; D000077211:Zoledronic Acid
D000726:Androgen Antagonists; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid